Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.
MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).
Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results